In pancreatic cancer, hepatocellular carcinoma, and prostate cancer, SQLE drives tumorigenesis through mechanisms such as activating the PI3K and TGF-β pathways, stimulating cholesterol ester synthesis, and upregulating NADP+ [14, 15, 18]. This evidence concerns the gene TGFB1 and prostate cancer.